Please login to the form below

Not currently logged in
Email:
Password:

J&J names McNeil Consumer leader

Johnson & Johnson has named Denice Torres, a former Lilly executive, to lead its McNeil Consumer Healthcare division, which recently has faced dozens of high-profile product recalls

Johnson & Johnson (J&J) has named Denice Torres, a former Lilly executive who has spent the past six years working at J&J, to lead its troubled McNeil Consumer Healthcare division, which recently has faced dozens of high-profile product recalls.

Torres, who will serve as president of the J&J unit, has been with the company since 2005, when she was hired to serve as VP, marketing, Ortho McNeil Neurologics.

In 2007, she became VP, sales & marketing, biosurgery and biopatch at J&J's medical devices company Ethicon, and in August 2009, she was named president, CNS, North America Pharmaceuticals.

Earlier in her career, Torres was with Eli Lilly for 14 years, becoming executive director by the time she left the company.

In her new position at J&J, Torres will report to Pat Mutchler, who was recently named chairman of a newly created McNeil group that is responsible for Tylenol, Motrin and other nonprescription J&J drugs.

Timeline of the McNeil Consumer Healthcare division events:
Tylenol recall prompts investigation    May 10, 2010
US recall of four children's products    June 1, 2010
Congress expands J&J probe    June 11, 2010
Johnson & Johnson cuts profit forecast    July 21, 2010
J&J consumer head retires amid probe    September 17, 2010
J&J recalls cold medications    November 26, 2010
FDA finds more problems at J&J plant    December 16, 2010
Oregon sues J&J over Motrin recall    January 13, 2011
More recalls by J&J's McNeil    January 17, 2011
J&J sales fall 0.5 per cent for 2010    January 26, 2011
FDA issues consent decree for J&J's McNeil    March 11, 2011

11th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...